/PRNewswire/ Mitsubishi Logisnext Americas group, a leading North American provider and manufacturer of material handling and innovative automation and.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (NASDAQ:OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company s diversified branded portfolio and Trigen Laboratories, LLC represents the Company s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its
® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program conducted by
MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
Upneeq
® provides patients and eye care providers with a safe and convenient non-surgical option to treat adults with acquired blepharoptosis (ptosis). The FDA-approved eye drop is the first and only therapeutic approved for the condition which previously required a surgical procedure. Upneeq
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company s diversified branded portfolio and Trigen Laboratories, LLC represents the Company s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson